Similar articles for PMID: 28914967

Year	Number of Results
2002	2
2004	2
2005	1
2006	4
2007	1
2008	5
2009	3
2010	4
2011	5
2012	11
2013	3
2014	7
2015	11
2016	15
2017	23
2018	35
2019	43
2020	29
2021	29
2022	17
2023	3
2024	0

1

The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.

Singh P, Kaushal V, Rai B, Rajwanshi A, Gupta N, Dey P, Garg R, Rohilla M, Suri V, Ghoshal S, Srinivasan R. Singh P, et al. Histopathology. 2018 Mar;72(4):619-625. doi: 10.1111/his.13399. Epub 2017 Dec 11. Histopathology. 2018. PMID: 28914967

2

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, Le ND, Gilks CB, Singh N. Böhm S, et al. J Clin Oncol. 2015 Aug 1;33(22):2457-63. doi: 10.1200/JCO.2014.60.5212. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124480

3

External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.

Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS. Lee JY, et al. J Gynecol Oncol. 2017 Nov;28(6):e73. doi: 10.3802/jgo.2017.28.e73. Epub 2017 Jul 24. J Gynecol Oncol. 2017. PMID: 28758379 Free PMC article.

4

A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?

Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A. Lawson BC, et al. Am J Surg Pathol. 2020 Feb;44(2):206-213. doi: 10.1097/PAS.0000000000001391. Am J Surg Pathol. 2020. PMID: 31651523 Free PMC article.

5

Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.

Biacchi D, Accarpio F, Ansaloni L, Macrì A, Ciardi A, Federici O, Spagnoli A, Cavaliere D, Vaira M, Sapienza P, Sammartino P. Biacchi D, et al. J Surg Oncol. 2019 Dec;120(7):1208-1219. doi: 10.1002/jso.25703. Epub 2019 Sep 17. J Surg Oncol. 2019. PMID: 31531879

6

Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.

Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G. Rajkumar S, et al. Gynecol Oncol. 2018 Nov;151(2):264-268. doi: 10.1016/j.ygyno.2018.08.042. Epub 2018 Sep 6. Gynecol Oncol. 2018. PMID: 30197060

7

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.

Lawson BC, Yang RK, Euscher ED, Ramalingam P, Malpica A. Lawson BC, et al. Hum Pathol. 2021 Sep;115:76-83. doi: 10.1016/j.humpath.2021.06.003. Epub 2021 Jun 19. Hum Pathol. 2021. PMID: 34153306

8

Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.

Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA. Coghlan E, et al. Int J Gynecol Cancer. 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945. Int J Gynecol Cancer. 2017. PMID: 28441251

9

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).

Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE. Ditzel HM, et al. Int J Gynecol Pathol. 2019 May;38(3):230-240. doi: 10.1097/PGP.0000000000000513. Int J Gynecol Pathol. 2019. PMID: 29750700

10

External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.

Zorzato PC, Zannoni GF, Tudisco R, Pasciuto T, Di Giorgio A, Franchi M, Scambia G, Fagotti A. Zorzato PC, et al. Int J Gynecol Cancer. 2020 Jan;30(1):67-73. doi: 10.1136/ijgc-2019-000561. Epub 2019 Nov 21. Int J Gynecol Cancer. 2020. PMID: 31754067

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

218 results

Results by year